Microalbuminuria in treated hypertensives: Only a mirror image of cardiovascular risk?

References

• Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature: Arch Intern Med 1997; 157: 1413–18
   Google Scholar
• Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 1999; 42: 263–85
   PubMed Web of Science ®Google Scholar
• Bog-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U. Survival in patients with hypertension treated in primary care: A population-based follow-up study in Skaraborg Hypertension and Diabetes Prosject. Scand J Prim Health Care 2004; 22: 222–7
   PubMed Web of Science ®Google Scholar
• Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992–7
   PubMed Web of Science ®Google Scholar
• Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519–26
   PubMed Web of Science ®Google Scholar
• Romundstad S, Holmen J, Hallan H, Kvenild K, Kruger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population: The Nord-Trondelag Health Study (HUNT, 1995–97), Norway. J Intern Med 2002; 252: 164–72
   PubMed Web of Science ®Google Scholar
• Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non-hypertensive persons identified in a large health screening––the Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol 2003; 59: 241–51
   PubMedGoogle Scholar
• Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325–33
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11: 430–8
   PubMed Web of Science ®Google Scholar
• Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727–32
   PubMedGoogle Scholar
• Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30: 1135–43
   PubMed Web of Science ®Google Scholar
• Viazzi F, Leoncini G, Parodi D, Ravera M, Ratto E, Vettoretti S, et al. Pulse pressure and subclinical cardiovascular damage in primary hypertension. Nephrol Dial Transplant 2002; 17: 1779–85
   PubMed Web of Science ®Google Scholar
• Martinez MA, Moreno A, Aguirre dC, Cabrera R, Rocha R, Torre A, et al. Frequency and determinants of microalbuminuria in mild hypertension: A primary-care-based study. J Hypertens 2001; 19: 319–26
   PubMedGoogle Scholar
• Pedrinelli R, Dell'Omo G, Penno G, Bandinelli S, Bertini A, Di B V, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48–54
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Lonati L, Sampieri L, Michev I, Macca G, Rocanova JI, et al. Prevalence of target organ damage in treated hypertensive patients: Different impact of clinic and ambulatory blood pressure control. J Hypertens 2000; 18: 803–9
   PubMed Web of Science ®Google Scholar
• Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39: 794–8
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53.
   PubMedGoogle Scholar
• Holmen J, Midthjell K, Krüger Ø, Langhammer A, Bratberg G, Vatten L, et al. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003; 13: 19–32
   Google Scholar
• Hallan H, Romundstad S, Kvenild K, Holmen J. Microalbuminuria in diabetic and hypertensive patients and the general population. Scand J Urol Nephrol 2003; 37: 151–8
   PubMed Web of Science ®Google Scholar
• Giampietro O, Penno G, Clerico A, Cruschelli L, Lucchetti A, Nannipieri M, et al. Which method for quantifying “microalbuminuria” in diabetics? Comparison of several immunological methods (immunoturbidimetric assay, immunonephelometric assay, radioimmunoassay and two semiquantitative tests) for measurement of albumin in urine. Acta Diabetol 1992; 28: 239–45
   PubMedGoogle Scholar
• Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab 2000; 46: 53–5
   PubMedGoogle Scholar
• Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997; 12(Suppl 2)6–9
   PubMedGoogle Scholar
• Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention?. J Hypertens 2003; 21: 1199–205
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206
   PubMed Web of Science ®Google Scholar
• Verhave JC, Hillege HL, Burgerhof JG, Navis G, De Zeeuw D, De Jong PE. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 2003; 14: 1330–5
   PubMed Web of Science ®Google Scholar
• Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001; 38: 1372–5
   PubMedGoogle Scholar
• Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307–13
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, et al. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2005; 16(Suppl 1)S39–S41
   Google Scholar
• Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, et al. Optimizing global risk evaluation in primary hypertension: The role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004; 22: 907–13
   PubMed Web of Science ®Google Scholar
• Getz L, Kirkengen AL, Hetlevik I, Romundstad S, Sigurdsson JA. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice: A descriptive epidemiological study. Scand J Prim Health Care 2004; 22: 202–8
   PubMed Web of Science ®Google Scholar
• Hetlevik I, Holmen J, Kruger O, Kristensen P, Iversen H. Implementing clinical guidelines in the treatment of hypertension in general practice. Blood Press 1998; 7: 270–6
   PubMedGoogle Scholar
• Getz L, Sigurdsson JA, Hetlevik I. Is opportunistic disease prevention in the consultation ethically justifiable?. BMJ 2003; 327: 498–500
   PubMed Web of Science ®Google Scholar